Previous 10 | Next 10 |
CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its second quarter 2022 financial re...
With earnings season beginning to ramp up, American Airlines ( NASDAQ: AAL ) got a boost in Tuesday's midday trading after releasing preliminary revenue figures. Signs of growth prompted a double-digit percentage rise in the stock price. Elsewhere, Herbalife ( HLF ) also sho...
Fulcrum Therapeutics ( NASDAQ: FULC ) on Monday said its chief medical officer Christopher Morabito will be leaving the company effective July 13. FULC said its R&D president Judith Dunn will be the interim chief medical officer while the company searches for a new exe...
CAMBRIDGE, Mass., July 11, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that Chief Medical Officer, Christopher Morabito, ...
Fulcrum Therapeutics ( NASDAQ: FULC ) said the first patient was dosed in a phase 3 trial of losmapimod to treat Facioscapulohumeral Muscular Dystrophy (FSHD). FSHD is a rare progressive disorder characterized by muscle weakness and wasting and initially affects t...
– REACH is the first Phase 3 trial for this rare, progressive, and debilitating muscular disease – – Losmapimod is an oral small molecule that has the potential to be the first therapy to treat FSHD, the second most common form of muscular dystrophy ...
Fulcrum lost hugely this month after announcing data from an early Sickle Cell Disease trial. The other program is also beset with issues. This does not look attractive to us right now. For further details see: Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telli...
MicroStrategy (MSTR) -25% as crypto market cap sinks below $1T. Astra Space (ASTR) -25% after latest mission failure. Qutoutiao (QTT) -21%. Marathon Digital Holdings (MARA) -17% as crypto market cap sinks below $1T. Bitfarms (BITF) -17% as cry...
The FDA will review Merck's (NYSE:MRK) supplemental Biologics License Application for Keytruda (pembrolizumab) as an adjuvant treatment for stage IB, II or IIIA non-small cell lung cancer following complete surgical resection. The action date for the application is Jan. 29, 2023. The applicat...
Disney (DIS) took another step down in Friday's midday action, as leadership drama at the entertainment giant propelled the latest retreat in a downtrend that has marked most of June so far. Meanwhile, Illumina (NASDAQ:ILMN) also lost ground on management uncertainty, with the stock dropping ...
News, Short Squeeze, Breakout and More Instantly...
Fulcrum Therapeutics Inc. Company Name:
FULC Stock Symbol:
NYSE Market:
Fulcrum Therapeutics Inc. Website:
CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...